The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 04 2022
09 04 2022
Historique:
received:
22
10
2021
accepted:
16
03
2022
entrez:
10
4
2022
pubmed:
11
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. The Pfizer-BioNTech COVID-19 vaccine COMIRNATY is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in COMIRNATY-vaccinated individuals. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from COMIRNATY vaccine recipients but not COVID-19 recovered patients. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine COMIRNATY.
Identifiants
pubmed: 35397679
doi: 10.1038/s41598-022-10057-7
pii: 10.1038/s41598-022-10057-7
pmc: PMC8994064
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Epitopes, B-Lymphocyte
0
Lipid Nanoparticles
0
Liposomes
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5999Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Lancet Respir Med. 2021 Jun;9(6):665-672
pubmed: 34000237
Cell Rep. 2021 Jan 26;34(4):108666
pubmed: 33503420
N Engl J Med. 2021 Apr 22;384(16):1576-1577
pubmed: 33596348
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Pharm Pract. 2021 Apr 12;:8971900211009650
pubmed: 33840294
Patient Saf Surg. 2021 May 1;15(1):20
pubmed: 33933145
Viruses. 2021 Jan 19;13(1):
pubmed: 33477902
Cell Mol Immunol. 2020 Oct;17(10):1095-1097
pubmed: 32895485
Front Immunol. 2021 Sep 21;12:707977
pubmed: 34621266
Cell. 2021 Jun 10;184(12):3192-3204.e16
pubmed: 33974910
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
NPJ Vaccines. 2021 Aug 16;6(1):104
pubmed: 34400651
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
J Clin Med. 2022 Jan 14;11(2):
pubmed: 35054099
Inflammopharmacology. 2021 Jun;29(3):645-649
pubmed: 33932192
Viruses. 2020 Jan 24;12(2):
pubmed: 31991541
Nucleic Acids Res. 2016 Jul 8;44(W1):W449-54
pubmed: 27131374
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
Nature. 2016 Mar 3;531(7592):118-21
pubmed: 26935699
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
J Med Virol. 2021 Oct;93(10):5729-5741
pubmed: 34125455
Lancet Microbe. 2022 Jan;3(1):e21-e31
pubmed: 34778853
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Nat Microbiol. 2021 Jul;6(7):899-909
pubmed: 33907312
J Immunol Methods. 2021 Aug;495:113082
pubmed: 34051226
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Cell Rep. 2021 Mar 30;34(13):108915
pubmed: 33761319
Nat Rev Immunol. 2021 Aug;21(8):475-484
pubmed: 34211186
Postgrad Med J. 2021 May;97(1147):312-320
pubmed: 32978337
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Nat Commun. 2020 Jun 1;11(1):2806
pubmed: 32483236
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246